Docetaxel as a Treatment for Advanced Gastrointestinal Cancers
Author Information
Author(s): Martin F. Sprinzl, Sonia M. Wytopil, Anja Dahmen, Stephan Kanzler, Peter R. Galle, Markus Moehler
Primary Institution: Johannes Gutenberg University, Mainz, Germany
Hypothesis
Can weekly docetaxel be an effective salvage therapy for patients with highly pretreated and drug-resistant gastrointestinal carcinomas?
Conclusion
Weekly docetaxel was well tolerated and provided a tumor control rate of 33.3% in patients with advanced gastrointestinal cancers.
Supporting Evidence
- Docetaxel was administered as second-line therapy in 28% of patients and third-line in 56%.
- Only one patient achieved a partial response, while 27.8% had stable disease.
- The median overall survival was 4.5 months for all patients.
Takeaway
This study looked at a medicine called docetaxel to help people with tough stomach cancers. It worked a little for some, but not for everyone.
Methodology
Eighteen patients received weekly docetaxel after previous treatments failed, and their responses were measured using RECIST criteria.
Potential Biases
Potential biases include selection bias due to the small, highly pretreated patient population.
Limitations
The study had a small sample size and was retrospective, which may limit the generalizability of the results.
Participant Demographics
Median age was 59.5 years; 72% had gastric cancer and 28% had bilio-pancreatic cancer.
Want to read the original?
Access the complete publication on the publisher's website